Sign up to access all valuation multiples
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
1999
16
LTM Revenue $62.1M
LTM EBITDA $28.3M
$197M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Clinuvel Pharmaceuticals has a last 12-month revenue (LTM) of $62.1M and a last 12-month EBITDA of $28.3M.
In the most recent fiscal year, Clinuvel Pharmaceuticals achieved revenue of $61.0M and an EBITDA of $36.7M.
Clinuvel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Clinuvel Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $62.1M | XXX | $61.0M | XXX | XXX | XXX |
| Gross Profit | $59.4M | XXX | $50.8M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $28.3M | XXX | $36.7M | XXX | XXX | XXX |
| EBITDA Margin | 46% | XXX | 60% | XXX | XXX | XXX |
| EBIT | $27.6M | XXX | $29.4M | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 48% | XXX | XXX | XXX |
| Net Profit | $23.5M | XXX | $23.2M | XXX | XXX | XXX |
| Net Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Clinuvel Pharmaceuticals's stock price is AUD 11 (or $7).
Clinuvel Pharmaceuticals has current market cap of AUD 530M (or $340M), and EV of AUD 306M (or $197M).
See Clinuvel Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $197M | $340M | XXX | XXX | XXX | XXX | $0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Clinuvel Pharmaceuticals has market cap of $340M and EV of $197M.
Clinuvel Pharmaceuticals's trades at 3.3x EV/Revenue multiple, and 5.4x EV/EBITDA.
Equity research analysts estimate Clinuvel Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Clinuvel Pharmaceuticals has a P/E ratio of 14.5x.
See valuation multiples for Clinuvel Pharmaceuticals and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $340M | XXX | $340M | XXX | XXX | XXX |
| EV (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.9x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBIT | 7.1x | XXX | 6.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.5x | XXX | 14.8x | XXX | XXX | XXX |
| EV/FCF | 7.6x | XXX | 8.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialClinuvel Pharmaceuticals's last 12 month revenue growth is 10%
Clinuvel Pharmaceuticals's revenue per employee in the last FY averaged $3.8M, while opex per employee averaged $1.3M for the same period.
Clinuvel Pharmaceuticals's rule of 40 is 71% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Clinuvel Pharmaceuticals's rule of X is 69% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Clinuvel Pharmaceuticals and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 46% | XXX | 62% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -7% | XXX | XXX | XXX |
| Rule of 40 | 71% | XXX | 71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Clinuvel Pharmaceuticals acquired XXX companies to date.
Last acquisition by Clinuvel Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Clinuvel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Clinuvel Pharmaceuticals founded? | Clinuvel Pharmaceuticals was founded in 1999. |
| Where is Clinuvel Pharmaceuticals headquartered? | Clinuvel Pharmaceuticals is headquartered in Australia. |
| How many employees does Clinuvel Pharmaceuticals have? | As of today, Clinuvel Pharmaceuticals has 16 employees. |
| Who is the CEO of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals's CEO is Dr. Philippe J. Wolgen, M.B.A.,M.D.. |
| Is Clinuvel Pharmaceuticals publicy listed? | Yes, Clinuvel Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals trades under CUV ticker. |
| When did Clinuvel Pharmaceuticals go public? | Clinuvel Pharmaceuticals went public in 2001. |
| Who are competitors of Clinuvel Pharmaceuticals? | Similar companies to Clinuvel Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals's current market cap is $340M |
| What is the current revenue of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals's last 12 months revenue is $62.1M. |
| What is the current revenue growth of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Clinuvel Pharmaceuticals? | Current revenue multiple of Clinuvel Pharmaceuticals is 3.2x. |
| Is Clinuvel Pharmaceuticals profitable? | Yes, Clinuvel Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals's last 12 months EBITDA is $28.3M. |
| What is Clinuvel Pharmaceuticals's EBITDA margin? | Clinuvel Pharmaceuticals's last 12 months EBITDA margin is 46%. |
| What is the current EV/EBITDA multiple of Clinuvel Pharmaceuticals? | Current EBITDA multiple of Clinuvel Pharmaceuticals is 6.9x. |
| What is the current FCF of Clinuvel Pharmaceuticals? | Clinuvel Pharmaceuticals's last 12 months FCF is $26.0M. |
| What is Clinuvel Pharmaceuticals's FCF margin? | Clinuvel Pharmaceuticals's last 12 months FCF margin is 42%. |
| What is the current EV/FCF multiple of Clinuvel Pharmaceuticals? | Current FCF multiple of Clinuvel Pharmaceuticals is 7.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
